ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

Selegiline
Parkinsonism
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

Selegiline Rx

Generic Name and Formulations:
Selegiline HCl 5mg; caps.

Company:
Various generic manufacturers

Therapeutic Use:

Indications for Selegiline:

Adjunct to levodopa/carbidopa in Parkinsonism.

Adult:

5mg at breakfast and at lunch; max 10mg/day. After 2–3 days, levodopa/carbidopa dosage may be reduced by 10–30%; further reductions may be possible later.

Children:

Not established.

Contraindications:

Concomitant meperidine, possibly other opioids.

Warnings/Precautions:

Selectivity for MAO type B diminishes at doses over 10mg/day. Pregnancy (Cat.C). Nursing mothers: not recommended.

Pharmacological Class:

MAO-B inhibitor.

Interactions:

See Contraindications. Avoid concomitant tricyclic antidepressants or selective serotonin reuptake inhibitors (SSRIs). Allow at least 5 weeks (or more if used chronically or at high doses) between fluoxetine discontinuance and 2 weeks between paroxetine or sertraline discontinuance before starting selegiline; allow 2 weeks between selegiline discontinuance before starting tricyclic antidepressants or SSRIs. Caution with tyramine-containing foods and with sympathomimetics.

Adverse Reactions:

Nausea, dizziness, lightheadedness, syncope, abdominal pain, confusion, vivid dreams, hallucinations, dry mouth, headache.

Note:

Formerly known under the brand name Eldepryl.

How Supplied:

Contact supplier

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs